Syndax Pharmaceuticals, Inc.
COMBINATION OF HDAC INHIBITOR AND ANTI-PD-L1 ANTIBODY FOR TREATMENT OF OVARIAN CANCER

Abstract:

Described herein are methods for the treatment of heavily pre-treated recurrent ovarian cancer. In particular, methods are provided for the treatment of heavily pre-treated recurrent ovarian cancer with a combination of entinostat and an anti-PD-L1 antibody.